ZNTL
NASDAQ
$5.01
Zentalis Pharmaceuticals Inc (ZNTL)
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapies for the treatment of various cancers. The company is headquartered in New York, New York.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $6.67 (+33.13%)
Market Cap
$340M
Free Cash Flow Yield
-36.93%
Beta (5Y)
1.73
Price Chart
Valuation
Market Cap$340M
P/S7.13
P/B1.86
Profitability
Gross Profit (TTM)$27M
EBITDA-$144M
EPS-$1.75
Financial Health
Free Cash Flow Yield-36.93%
Growth & Risk
EPS 5Y CAGR-14.37%
FCF 5Y CAGR+2.95%
Beta (5Y)1.73
Sharpe Ratio1.51